Published in J Intern Med on March 01, 2006
2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol (2009) 5.65
Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol (2006) 4.02
Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation (2009) 3.93
LDL Particle Number and Risk of Future Cardiovascular Disease in the Framingham Offspring Study - Implications for LDL Management. J Clin Lipidol (2007) 2.21
Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey. Drug Des Devel Ther (2011) 1.68
Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention. Vasc Health Risk Manag (2009) 1.59
The joint effects of apolipoprotein B, apolipoprotein A1, LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls. Eur Heart J (2009) 1.52
Very low density lipoprotein cholesterol associates with coronary artery calcification in type 2 diabetes beyond circulating levels of triglycerides. Atherosclerosis (2014) 1.45
Dietary carbohydrate restriction in type 2 diabetes mellitus and metabolic syndrome: time for a critical appraisal. Nutr Metab (Lond) (2008) 1.44
Association of apolipoprotein A1 and B with kidney function and chronic kidney disease in two multiethnic population samples. Nephrol Dial Transplant (2012) 1.43
Impact of an integrated obesity management system on patient's care - research protocol. BMC Obes (2014) 1.39
The role of triglycerides in atherosclerosis. Curr Cardiol Rep (2011) 1.38
Association of high-density lipoprotein cholesterol with incident cardiovascular events in women, by low-density lipoprotein cholesterol and apolipoprotein B100 levels: a cohort study. Ann Intern Med (2011) 1.20
Discordance between non-HDL-cholesterol and LDL-particle measurements: results from the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis (2013) 1.19
Effects of rosuvastatin and atorvastatin on LDL and HDL particle concentrations in patients with metabolic syndrome: a randomized, double-blind, controlled study. Diabetes Care (2009) 1.14
Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events. Circulation (2013) 1.10
Analysis of recently identified dyslipidemia alleles reveals two loci that contribute to risk for carotid artery disease. Lipids Health Dis (2009) 1.03
Advanced lipoprotein testing and subfractionation are not (yet) ready for routine clinical use. Circulation (2009) 1.03
Diabetes, abdominal adiposity, and atherogenic dyslipoproteinemia in women compared with men. Diabetes (2008) 1.02
Apolipoprotein B but not LDL cholesterol is associated with coronary artery calcification in type 2 diabetic whites. Diabetes (2009) 1.02
Using apolipoprotein B to manage dyslipidemic patients: time for a change? Mayo Clin Proc (2010) 0.94
Diagnosis and treatment of apolipoprotein B dyslipoproteinemias. Nat Rev Endocrinol (2010) 0.93
Association of apolipoprotein B with incident type 2 diabetes in an aboriginal Canadian population. Clin Chem (2010) 0.92
Low-density lipoprotein cholesterol estimation by the Anandaraja's formula--confirmation. Lipids Health Dis (2006) 0.92
Low carbohydrate diets improve atherogenic dyslipidemia even in the absence of weight loss. Nutr Metab (Lond) (2006) 0.91
Implications of the obesity epidemic for lipid-lowering therapy: non-HDL cholesterol should replace LDL cholesterol as the primary therapeutic target. Vasc Health Risk Manag (2008) 0.90
Identification of two common variants contributing to serum apolipoprotein B levels in Mexicans. Arterioscler Thromb Vasc Biol (2009) 0.90
The association between obesity, cardiometabolic disease biomarkers, and innate immunity-related inflammation in Canadian adults. Diabetes Metab Syndr Obes (2012) 0.88
Serum n-6 fatty acids and lipoprotein subclasses in middle-aged men: the population-based cross-sectional ERA-JUMP study. Am J Clin Nutr (2010) 0.87
Opening a new lipid "apo-thecary": incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular risk. Mayo Clin Proc (2011) 0.87
Elevated oxidative stress among coronary artery disease patients on statin therapy: A cross sectional study. Indian Heart J (2015) 0.87
Estimation of plasma apolipoprotein B concentration using routinely measured lipid biochemical tests in apparently healthy Asian adults. Cardiovasc Diabetol (2012) 0.85
Tolerability, pharmacokinetics and pharmacodynamics of TA-8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Br J Clin Pharmacol (2014) 0.84
Evidence of how rs7575840 influences apolipoprotein B-containing lipid particles. Arterioscler Thromb Vasc Biol (2011) 0.84
Biomarkers of atherosclerosis: clinical applications. Curr Cardiol Rep (2008) 0.83
Multivessel coronary artery disease, free fatty acids, oxidized LDL and its antibody in myocardial infarction. Lipids Health Dis (2014) 0.83
Apo B/Apo A-I Ratio is Statistically A Better Predictor of Cardiovascular Disease (CVD) than Conventional Lipid Profile: A Study from Kathmandu Valley, Nepal. J Clin Diagn Res (2014) 0.83
Nonstatin Low-Density Lipoprotein-Lowering Therapy and Cardiovascular Risk Reduction-Statement From ATVB Council. Arterioscler Thromb Vasc Biol (2015) 0.83
ApoB/apoA1 is an effective predictor of coronary heart disease risk in overweight and obesity. J Biomed Res (2011) 0.83
Serum calcium levels are associated with novel cardiometabolic risk factors in the population-based CoLaus study. PLoS One (2011) 0.82
Common medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile? Cardiovasc Diabetol (2016) 0.81
Liposcale: a novel advanced lipoprotein test based on 2D diffusion-ordered 1H NMR spectroscopy. J Lipid Res (2015) 0.81
An equation to estimate the concentration of serum apolipoprotein B. PLoS One (2012) 0.81
Lipid lowering therapy in type 2 diabetes. Wien Med Wochenschr (2011) 0.80
Benefits & risks of statin therapy for primary prevention of cardiovascular disease in Asian Indians - a population with the highest risk of premature coronary artery disease & diabetes. Indian J Med Res (2013) 0.79
Work and diet-related risk factors of cardiovascular diseases: comparison of two occupational groups. J Occup Med Toxicol (2010) 0.79
Effects of isoflavones on lipid and apolipoprotein levels in patients with type 2 diabetes in Heilongjiang Province in China. J Clin Biochem Nutr (2016) 0.77
Achieving secondary prevention low-density lipoprotein particle concentration goals using lipoprotein cholesterol-based data. PLoS One (2012) 0.77
The evolution and refinement of traditional risk factors for cardiovascular disease. Cardiol Rev (2012) 0.77
Prediction of risk factors for coronary heart disease using Framingham Risk Score in Korean men. PLoS One (2012) 0.77
Low density lipoprotein cholesterol is inversely correlated with abdominal visceral fat area: a magnetic resonance imaging study. Lipids Health Dis (2011) 0.77
The relation between dietary intake of vegetable oils and serum lipids and apolipoprotein levels in central Iran. ARYA Atheroscler (2012) 0.76
Relation of Combined Non-High-Density Lipoprotein Cholesterol and Apolipoprotein B With Atherosclerosis in Adults With Type 1 Diabetes Mellitus. Am J Cardiol (2015) 0.76
Association of apolipoprotein B, LDL-C and vascular stiffness in adolescents with type 1 diabetes. Acta Diabetol (2014) 0.76
Association of height and pubertal timing with lipoprotein subclass profile: exploring the role of genetic and environmental effects. Am J Hum Biol (2013) 0.76
Ethanol Extract of Persimmon Tree Leaves Improves Blood Circulation and Lipid Metabolism in Rats Fed a High-Fat Diet. J Med Food (2015) 0.76
Associations between intensive diabetes therapy and NMR-determined lipoprotein subclass profiles in type 1 diabetes. J Lipid Res (2015) 0.76
The common apolipoprotein A-1 polymorphism -75A>G is associated with ethnic differences in recurrent coronary events after recovery from an acute myocardial infarction. Heart Int (2009) 0.76
Quantification of concordance and discordance between apolipoprotein-B and the currently recommended non-HDL-cholesterol goals for cardiovascular risk assessment in patients with diabetes and hypertriglyceridemia. Diabetes Res Clin Pract (2012) 0.76
Lipid lowering efficacy and safety of Ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients. Lipids Health Dis (2015) 0.75
Effects of a purified krill oil phospholipid rich in long-chain omega-3 fatty acids on cardiovascular disease risk factors in non-human primates with naturally occurring diabetes type-2 and dyslipidemia. Lipids Health Dis (2017) 0.75
Long-term Expression of Apolipoprotein B mRNA-specific Hammerhead Ribozyme via scAAV8.2 Vector Inhibits Atherosclerosis in Mice. Mol Ther Nucleic Acids (2013) 0.75
Risk factors and assessment for cardiovascular disease among HIV-positive patients attending a Nigerian tertiary hospital. Pan Afr Med J (2016) 0.75
Correlation of metabolic syndrome severity with cardiovascular health markers in adolescents. Metabolism (2017) 0.75
Method for estimating high sdLDL-C by measuring triglyceride and apolipoprotein B levels. Lipids Health Dis (2017) 0.75
Prospects and limitations of antibody-mediated clearing of lipoproteins from blood plasma prior to nanoparticle tracking analysis of extracellular vesicles. J Extracell Vesicles (2017) 0.75
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med (1995) 28.35
The Cardiovascular Health Study: design and rationale. Ann Epidemiol (1991) 27.24
Global health 2035: a world converging within a generation. Lancet (2013) 16.85
Priority actions for the non-communicable disease crisis. Lancet (2011) 15.18
Towards a common definition of global health. Lancet (2009) 12.36
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J (2011) 10.52
Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes (1997) 8.96
An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science (2001) 8.73
Incidence of and risk factors for atrial fibrillation in older adults. Circulation (1997) 8.18
Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) Diabetes Care (1997) 7.85
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med (2001) 7.69
Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation (2000) 7.37
Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet (1999) 7.30
Expansion of cancer care and control in countries of low and middle income: a call to action. Lancet (2010) 6.84
Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science (2000) 6.73
High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet (2001) 6.31
Gene Ontology annotations and resources. Nucleic Acids Res (2012) 6.13
Catheter technique for recording His bundle activity in man. Circulation (1969) 6.01
Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA (1997) 5.91
Coronary risk factors in people from the Indian subcontinent living in west London and their siblings in India. Lancet (1995) 5.79
Chronic diseases now a leading cause of death in rural India--mortality data from the Andhra Pradesh Rural Health Initiative. Int J Epidemiol (2006) 5.60
Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. Lancet (2000) 5.42
Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry data. Lancet (2008) 5.27
Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis (2000) 4.88
Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med (2000) 4.84
Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA (2013) 4.82
The MOGE(S) classification for a phenotype-genotype nomenclature of cardiomyopathy: endorsed by the World Heart Federation. J Am Coll Cardiol (2013) 4.81
AHA Dietary Guidelines: revision 2000: A statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Circulation (2000) 4.80
Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group. Am J Hypertens (1996) 4.66
Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation (1997) 4.41
Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. Diabetologia (2010) 4.33
Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation (2001) 4.32
Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J (2010) 4.31
Management of hyperlipidaemia: guidelines of the British Hyperlipidaemia Association. Postgrad Med J (1993) 4.28
Chronic diseases and injuries in India. Lancet (2011) 4.27
A ligand-gated association between cytoplasmic domains of UNC5 and DCC family receptors converts netrin-induced growth cone attraction to repulsion. Cell (1999) 4.25
Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation (2001) 4.21
Effects of acculturation and socioeconomic status on obesity and diabetes in Mexican Americans. The San Antonio Heart Study. Am J Epidemiol (1988) 4.20
Burden of non-communicable diseases in South Asia. BMJ (2004) 4.19
Noncommunicable diseases. N Engl J Med (2013) 4.17
Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs. Lancet (2007) 4.15
Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol (1994) 4.08
Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation (1990) 3.83
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol (2007) 3.81
LMNA, encoding lamin A/C, is mutated in partial lipodystrophy. Nat Genet (2000) 3.73
A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA (1996) 3.69
UN High-Level Meeting on Non-Communicable Diseases: addressing four questions. Lancet (2011) 3.68
Relative contribution of LFA-1 and Mac-1 to neutrophil adhesion and migration. J Immunol (1999) 3.67
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J (2013) 3.58
Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation (2001) 3.57
Inflammatory and immune responses are impaired in mice deficient in intercellular adhesion molecule 1. Proc Natl Acad Sci U S A (1993) 3.57
Prevention of cardiovascular disease in general practice: a proposed model. Br Med J (Clin Res Ed) (1986) 3.56
Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med (2011) 3.52
Errors in the polymerase chain reaction. Nucleic Acids Res (1988) 3.52
Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis (1998) 3.50
Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia (1991) 3.48
Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature (1991) 3.48
The relation of body fat mass and distribution to markers of chronic inflammation. Int J Obes Relat Metab Disord (2001) 3.39
Myocardial ischemia and reperfusion: a murine model. Am J Physiol (1995) 3.38
Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study. Diabetes Care (1998) 3.34
Infertility in male pesticide workers. Lancet (1977) 3.29
Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old. Lancet (1996) 3.28
Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol (2003) 3.26
Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev (2006) 3.26
[The Scandinavian Simvastatin Survival Study]. Ugeskr Laeger (1995) 3.25
Scaling up interventions for chronic disease prevention: the evidence. Lancet (2007) 3.24
Time to act on drug safety. JAMA (1998) 3.22
Primary prevention of coronary heart disease: guidance from Framingham: a statement for healthcare professionals from the AHA Task Force on Risk Reduction. American Heart Association. Circulation (1998) 3.18
The effect of rural-to-urban migration on obesity and diabetes in India: a cross-sectional study. PLoS Med (2010) 3.16
Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett (1991) 3.10
Reductase inhibitor monotherapy and stroke prevention. Arch Intern Med (1997) 3.05
Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA (1988) 3.04
Prevalence and etiology of idiopathic dilated cardiomyopathy (summary of a National Heart, Lung, and Blood Institute workshop. Am J Cardiol (1992) 3.03
Immunosuppression and plasma-exchange in the treatment of Goodpasture's syndrome. Lancet (1976) 3.00
The association of antihypertensive agents with MRI white matter findings and with Modified Mini-Mental State Examination in older adults. J Am Geriatr Soc (1997) 2.98
Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation (2000) 2.96
The emerging role of electronic medical records in pharmacogenomics. Clin Pharmacol Ther (2011) 2.93
Validity of cardiovascular disease risk factors assessed by telephone survey: the Behavioral Risk Factor Survey. J Clin Epidemiol (1993) 2.91
The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther (2012) 2.90
High-monounsaturated fatty acid diets lower both plasma cholesterol and triacylglycerol concentrations. Am J Clin Nutr (1999) 2.89
Gestational weight gain and postpartum behaviors associated with weight change from early pregnancy to 1 y postpartum. Int J Obes Relat Metab Disord (2003) 2.89
Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA (1996) 2.89
American Heart Association call to action: obesity as a major risk factor for coronary heart disease. AHA Nutrition Committee. Circulation (1998) 2.84
British guidelines on managing hypertension. Provide evidence, progress, and an occasional missed opportunity. BMJ (1999) 2.83
The effects of drug treatment for hypertension on morbidity and mortality from cardiovascular disease: a review of randomized controlled trials. Prog Cardiovasc Dis (1987) 2.77
Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects. Circulation (2005) 2.77
Chronic heart failure in Australian general practice. The Cardiac Awareness Survey and Evaluation (CASE) Study. Med J Aust (2001) 2.71
The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)). Clin Biochem (2001) 2.71
LFA-1 is sufficient in mediating neutrophil emigration in Mac-1-deficient mice. J Clin Invest (1997) 2.71
Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res (1982) 2.71
Depressive symptoms and risks of coronary heart disease and mortality in elderly Americans. Cardiovascular Health Study Collaborative Research Group. Circulation (2000) 2.71